Meningococcal 4-valent conjugate superior to polysaccharide vaccine

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1478, 2005-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed): In Older Adults

By Sanford Mark  

Drugs, Vol. 72, Iss. 9, 2012-06 ,pp. : 1243-1255

Adis International

Access to resources Recommend Favorite

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]

By Duggan Sean T.  

Drugs, Vol. 70, Iss. 15, 2010-10 ,pp. : 1973-1986

Adis International

Access to resources Recommend Favorite

Pneumococcal Polysaccharide Conjugate Vaccine (13-Valent, Adsorbed) [Prevenar 13®]†: Profile Report

By Duggan Sean T.  

Pediatric Drugs, Vol. 14, Iss. 1, 2012-02 ,pp. : 67-69

Adis International

Access to resources Recommend Favorite

Vaccines: Hyperhaemolysis (first reports with meningococcal vaccine groups A C Y W-135 polysaccharide and Hib vaccine conjugate) in an EBV-infected patient: case report

By  

Reactions Weekly, Vol. 1, Iss. 1278, 2009-01 ,pp. : 29-30

Adis International

Access to resources Recommend Favorite

Meningococcal group C conjugate vaccine immunogenic in infants

By  

Inpharma, Vol. 1, Iss. 1242, 2000-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite